Abstract
Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.
MeSH terms
-
Androgen Receptor Antagonists / therapeutic use
-
Androstenes / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Bone Density Conservation Agents / therapeutic use
-
Bone Neoplasms / prevention & control*
-
Bone Neoplasms / secondary
-
Cost-Benefit Analysis
-
Denosumab
-
Diphosphonates / therapeutic use
-
Enzyme Inhibitors / therapeutic use
-
Fractures, Spontaneous / prevention & control*
-
Humans
-
Imidazoles / therapeutic use
-
Male
-
Nitriles
-
Pain / drug therapy*
-
Pain / etiology
-
Phenylthiohydantoin / analogs & derivatives
-
Phenylthiohydantoin / therapeutic use
-
Prostatic Neoplasms, Castration-Resistant / drug therapy
-
Prostatic Neoplasms, Castration-Resistant / pathology*
-
Quality of Life
-
Radioisotopes / therapeutic use
-
Radium / therapeutic use
-
Spinal Cord Compression / prevention & control*
-
Zoledronic Acid
Substances
-
Androgen Receptor Antagonists
-
Androstenes
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Benzamides
-
Bone Density Conservation Agents
-
Diphosphonates
-
Enzyme Inhibitors
-
Imidazoles
-
Nitriles
-
Radioisotopes
-
Phenylthiohydantoin
-
Denosumab
-
Zoledronic Acid
-
enzalutamide
-
abiraterone
-
Radium